Our Products News
-
Ribo expands beyond the liver with RiboPepSTAR™ – enabling targeted siRNA delivery to multiple organsRibo expands beyond the liver with RiboPepSTAR™ – enabling targeted siRNA delivery to multiple organsMarch 20, 2026 -
Ribo to present ex-hepatic delivery data at RNA Leaders Europe ConferenceRibo has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.March 17, 2026 -
Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.March 2, 2026 -
Recent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapyRecent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapyFebruary 9, 2026 -
Ribo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in ChinaRibo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in ChinaJanuary 23, 2026 -
Ribo Presents Kidney-Targeted Delivery Data at ASN Kidney Week 2025Ribo recently presented a poster at the ASN Kidney Week in Texas, showcasing the kidney-targeted delivery of siRNA using its RiboPepSTAR™ peptide conjugates.December 4, 2025